secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001193125-23-233019
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma President & COO Swisher to retire; CFO Galá promoted to COO; interim CFO named
--------------------------------------------------------------------------------

- Daniel Swisher Jr., President & COO, to retire effective Mar 31, 2024; duties cease Oct 1, 2023.
- Renée Galá, former EVP & CFO, appointed President & COO effective Oct 1, 2023.
- Galá's base salary raised to $800K (from $735K), target bonus 75% (from 60%), plus $200K one-time equity.
- Patricia Carr, SVP & Chief Accounting Officer, named interim principal financial officer while CFO search underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/0001193125-23-233019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/d539884d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer